Conditions:   Hemodialysis Catheter Blood Stream Infection;   Central Line Infection;   Dialysis Line Thrombosis
Interventions:   Device: TEGO;   Device: Standard
Sponsor:   Beaumont Hospital
Enrolling by invitation - verified January 2010

Conditions:   Fallopian Tube Cancer;   Ovarian Sarcoma;   Ovarian Stromal Cancer;   Recurrent Cervical Cancer;   Recurrent Endometrial Carcinoma;   Recurrent Ovarian Epithelial Cancer;   Recurrent Ovarian Germ Cell Tumor;   Recurrent Uterine Sarcoma;   Recurrent Vaginal Cancer;   Recurrent Vulvar Cancer;   Stage III Cervical Cancer;   Stage III Endometrial Carcinoma;   Stage III Ovarian Epithelial Cancer;   Stage III Ovarian Germ Cell Tumor;   Stage III Uterine Sarcoma;   Stage III Vaginal Cancer;   Stage III Vulvar Cancer;   Stage IV Endometrial Carcinoma;   Stage IV Ovarian Epithelial Cancer;   Stage IV Ovarian Germ Cell Tumor;   Stage IV Uterine Sarcoma;   Stage IV Vulvar Cancer;   Stage IVA Cervical Cancer;   Stage IVA Vaginal Cancer;   Stage IVB Cervical Cancer;   Stage IVB Vaginal Cancer
Interventions:   Radiation: stereotactic radiosurgery;   Procedure: quality-of-life assessment
Sponsor:   Case Comprehensive Cancer Center
Recruiting - verified March 2010

Condition:   Cardiovascular Diseases
Interventions:   Drug: polypill;   Drug: Usual cardiovascular medications
Sponsors:   Imperial College London;   European Commission;   Imperial College Healthcare NHS Trust;   Royal College of Surgeons, Ireland;   UMC Utrecht;   The George Institute for International Health India;   Public Health Foundation of India;   The George Institute;   Dr. Reddy's Laboratories Limited
Not yet recruiting - verified March 2010

Conditions:   Breast Cancer;   Inflammatory Breast Cancer;   Stage I Breast Cancer;   Stage II Breast Cancer;   Stage IIIA Breast Cancer;   Stage IIIB Breast Cancer;   Stage IIIC Breast Cancer;   Triple-negative Breast Cancer
Interventions:   Biological: MUC-1 peptide vaccine;   Biological: poly ICLC;   Biological: MUC1 peptide-poly-ICLC adjuvant vaccine;   Other: laboratory biomarker analysis;   Other: enzyme-linked immunosorbent assay;   Other: flow cytometry
Sponsor:   Case Comprehensive Cancer Center
Recruiting - verified February 2010

Condition:   Colorectal Cancer
Interventions:   Biological: bevacizumab;   Biological: cetuximab;   Drug: fluorouracil;   Drug: irinotecan hydrochloride;   Drug: leucovorin calcium;   Drug: oxaliplatin;   Genetic: RNA analysis;   Genetic: cytogenetic analysis;   Genetic: fluorescence in situ hybridization;   Genetic: gene expression analysis;   Genetic: mutation analysis;   Genetic: protein expression analysis;   Other: diagnostic laboratory biomarker analysis;   Other: immunohistochemistry staining method;   Other: questionnaire administration;   Procedure: cognitive assessment
Sponsor:   Medical Research Council
Recruiting - verified February 2010

Condition:   Breast Cancer
Interventions:   Radiation: intracavitary balloon brachytherapy;   Radiation: intraoperative radiation therapy
Sponsors:   Case Comprehensive Cancer Center;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Conditions:   Cervical Cancer;   Therapy-related Toxicity;   Vaginal Cancer
Interventions:   Drug: cisplatin;   Drug: triapine;   Other: questionnaire administration;   Procedure: assessment of therapy complications;   Procedure: computed tomography;   Procedure: quality-of-life assessment;   Radiation: fludeoxyglucose F 18;   Radiation: radiation therapy
Sponsors:   Case Comprehensive Cancer Center;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Breast Cancer
Interventions:   Other: immunoenzyme technique;   Other: laboratory biomarker analysis
Sponsors:   Case Comprehensive Cancer Center;   National Cancer Institute (NCI)
Completed - verified March 2010

Condition:   Unspecified Adult Solid Tumor, Protocol Specific
Interventions:   Drug: methoxyamine;   Drug: temozolomide;   Genetic: DNA analysis;   Other: laboratory biomarker analysis;   Other: pharmacological study
Sponsors:   Case Comprehensive Cancer Center;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Conditions:   Down Syndrome;   Trisomy 21
Intervention:  
Sponsors:   Women and Infants Hospital of Rhode Island;   Sequenom, Inc.
Recruiting - verified February 2010

Conditions:   Cervical Cancer;   Endometrial Cancer;   Fallopian Tube Cancer;   Ovarian Cancer;   Sarcoma;   Vaginal Cancer;   Vulvar Cancer
Interventions:   Drug: topotecan hydrochloride;   Other: pharmacological study
Sponsors:   Case Comprehensive Cancer Center;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Brain and Central Nervous System Tumors
Intervention:   Drug: aminolevulinic acid
Sponsors:   Case Comprehensive Cancer Center;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Conditions:   Adenocarcinoma of the Gastroesophageal Junction;   Esophageal Cancer
Interventions:   Drug: docetaxel;   Drug: oxaliplatin;   Drug: vandetanib;   Other: placebo
Sponsors:   Case Comprehensive Cancer Center;   National Cancer Institute (NCI)
Recruiting - verified February 2010

Condition:   Lung Cancer
Interventions:   Drug: cisplatin;   Drug: etoposide;   Drug: sorafenib tosylate
Sponsors:   Case Comprehensive Cancer Center;   National Cancer Institute (NCI)
Suspended - verified March 2010

Condition:   Head and Neck Cancer
Interventions:   Drug: docetaxel;   Drug: erlotinib hydrochloride;   Genetic: fluorescence in situ hybridization;   Genetic: polymerase chain reaction;   Other: immunoenzyme technique;   Other: immunohistochemistry staining method;   Other: laboratory biomarker analysis;   Other: pharmacological study;   Procedure: therapeutic conventional surgery;   Radiation: intensity-modulated radiation therapy;   Radiation: radiation therapy
Sponsors:   Case Comprehensive Cancer Center;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Acute Coronary Syndrome
Interventions:   Drug: Clopidogrel;   Drug: Prasugrel;   Drug: Commercially-available Aspirin
Sponsors:   Eli Lilly and Company;   Daiichi Sankyo Co., Ltd.;   Duke University
Recruiting - verified March 2010

Condition:   Lung Cancer
Interventions:   Drug: erlotinib hydrochloride;   Drug: pemetrexed disodium
Sponsors:   Case Comprehensive Cancer Center;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Prostate Cancer
Interventions:   Other: questionnaire administration;   Procedure: quality-of-life assessment;   Radiation: stereotactic radiosurgery
Sponsors:   Case Comprehensive Cancer Center;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Unspecified Adult Solid Tumor, Protocol Specific
Intervention:   Drug: CC-4047
Sponsors:   Case Comprehensive Cancer Center;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Pelvic Organ Prolapse
Intervention:   Procedure: Pelvic Floor Muscle Training
Sponsors:   Glasgow Caledonian University;   Chief Scientist Office of the Scottish Government;   South Glasgow University Hospitals NHS Trust;   University of Aberdeen;   University of Otago
Active, not recruiting - verified February 2010

Condition:   Pancreatic Cancer
Interventions:   Drug: dasatinib;   Other: laboratory biomarker analysis;   Other: physiologic testing
Sponsors:   Case Comprehensive Cancer Center;   National Cancer Institute (NCI)
Recruiting - verified February 2010

Conditions:   Pancreatic Cancer;   Unspecified Adult Solid Tumor, Protocol Specific
Interventions:   Drug: gemcitabine hydrochloride;   Drug: sunitinib malate
Sponsors:   Case Comprehensive Cancer Center;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Kidney Cancer
Intervention:   Radiation: stereotactic radiosurgery
Sponsors:   Case Comprehensive Cancer Center;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Kidney Cancer
Interventions:   Procedure: conventional surgery;   Radiation: stereotactic radiosurgery
Sponsors:   Case Comprehensive Cancer Center;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Kidney Cancer
Intervention:   Drug: tandutinib
Sponsors:   Case Comprehensive Cancer Center;   National Cancer Institute (NCI)
Completed - verified March 2010

Conditions:   Leukemia;   Long-term Effects Secondary to Cancer Therapy in Adults;   Long-term Effects Secondary to Cancer Therapy in Children;   Lymphoma;   Sexual Dysfunction and Infertility;   Sexuality and Reproductive Issues;   Unspecified Adult Solid Tumor, Protocol Specific;   Unspecified Childhood Solid Tumor, Protocol Specific
Interventions:   Other: laboratory biomarker analysis;   Procedure: fertility assessment and management;   Procedure: management of therapy complications;   Procedure: ultrasound imaging
Sponsors:   Case Comprehensive Cancer Center;   National Cancer Institute (NCI)
Recruiting - verified February 2010

Condition:   Cancer
Interventions:   Biological: graft versus host disease prophylaxis/therapy;   Genetic: fluorescence in situ hybridization;   Other: immunoenzyme technique;   Other: immunohistochemistry staining method;   Other: laboratory biomarker analysis;   Procedure: in vitro-treated bone marrow transplantation;   Procedure: management of therapy complications
Sponsors:   Case Comprehensive Cancer Center;   National Cancer Institute (NCI)
Active, not recruiting - verified March 2010

Condition:   Unspecified Adult Solid Tumor, Protocol Specific
Interventions:   Biological: bevacizumab;   Drug: sunitinib malate
Sponsors:   Case Comprehensive Cancer Center;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Conditions:   Cervical Cancer;   Endometrial Cancer;   Ovarian Cancer;   Vaginal Cancer;   Vulvar Cancer
Interventions:   Drug: cisplatin;   Drug: triapine;   Genetic: molecular diagnostic method;   Other: flow cytometry;   Other: immunoenzyme technique;   Other: pharmacological study;   Radiation: brachytherapy;   Radiation: radiation therapy
Sponsors:   Case Comprehensive Cancer Center;   National Cancer Institute (NCI)
Completed - verified March 2010

Condition:   Breast Cancer
Interventions:   Drug: anastrozole;   Drug: chemotherapy;   Drug: exemestane;   Drug: letrozole;   Drug: tamoxifen citrate
Sponsors:   Eastern Cooperative Oncology Group;   National Cancer Institute (NCI);   Southwest Oncology Group;   Cancer and Leukemia Group B;   American College of Surgeons;   North Central Cancer Treatment Group;   NCIC Clinical Trials Group;   National Surgical Adjuvant Breast and Bowel Project (NSABP)
Recruiting - verified March 2010

Conditions:   Colorectal Cancer;   Unspecified Adult Solid Tumor, Protocol Specific
Interventions:   Biological: bevacizumab;   Drug: capecitabine;   Drug: irinotecan hydrochloride;   Drug: oxaliplatin
Sponsors:   Case Comprehensive Cancer Center;   National Cancer Institute (NCI)
Active, not recruiting - verified March 2010

Condition:   Head and Neck Cancer
Interventions:   Biological: bevacizumab;   Drug: docetaxel;   Procedure: conventional surgery;   Radiation: radiation therapy
Sponsors:   Case Comprehensive Cancer Center;   National Cancer Institute (NCI)
Active, not recruiting - verified March 2010

Conditions:   Neurotoxicity;   Unspecified Adult Solid Tumor, Protocol Specific
Intervention:   Procedure: management of therapy complications
Sponsors:   Case Comprehensive Cancer Center;   National Cancer Institute (NCI)
Completed - verified February 2010

Condition:   Breast Cancer
Interventions:   Drug: anastrozole;   Drug: exemestane;   Drug: letrozole
Sponsors:   American College of Surgeons;   National Cancer Institute (NCI);   Cancer and Leukemia Group B
Recruiting - verified March 2010

Conditions:   Neurotoxicity;   Unspecified Adult Solid Tumor, Protocol Specific
Intervention:   Procedure: management of therapy complications
Sponsors:   Case Comprehensive Cancer Center;   National Cancer Institute (NCI)
Completed - verified March 2010

Conditions:   Endometrial Cancer;   Weight Changes
Interventions:   Behavioral: behavioral dietary intervention;   Other: counseling intervention;   Other: educational intervention;   Other: preventative dietary intervention;   Procedure: quality-of-life assessment
Sponsors:   Case Comprehensive Cancer Center;   National Cancer Institute (NCI)
Active, not recruiting - verified February 2010

Conditions:   Cervical Cancer;   Diarrhea;   Prostate Cancer;   Radiation Toxicity;   Sarcoma
Interventions:   Dietary Supplement: dietary intervention;   Procedure: management of therapy complications;   Procedure: quality-of-life assessment
Sponsors:   Case Comprehensive Cancer Center;   National Cancer Institute (NCI)
Active, not recruiting - verified March 2010

Condition:   Brain and Central Nervous System Tumors
Interventions:   Radiation: radiation therapy;   Radiation: stereotactic radiosurgery
Sponsors:   Case Comprehensive Cancer Center;   National Cancer Institute (NCI)
Active, not recruiting - verified March 2010

Conditions:   Lung Cancer;   Metastatic Cancer;   Ovarian Cancer;   Unspecified Adult Solid Tumor, Protocol Specific
Interventions:   Procedure: computed tomography;   Procedure: positron emission tomography;   Radiation: 11C topotecan;   Radiation: fludeoxyglucose F 18
Sponsors:   Case Comprehensive Cancer Center;   National Cancer Institute (NCI)
Completed - verified March 2010

Condition:   Head and Neck Cancer
Intervention:   Drug: sorafenib tosylate
Sponsors:   Case Comprehensive Cancer Center;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Brain and Central Nervous System Tumors
Interventions:   Drug: porfimer sodium;   Procedure: adjuvant therapy;   Procedure: conventional surgery
Sponsors:   Case Comprehensive Cancer Center;   National Cancer Institute (NCI)
Completed - verified February 2010

Conditions:   Cervical Cancer;   Endometrial Cancer;   Ovarian Cancer;   Vaginal Cancer
Interventions:   Drug: capecitabine;   Radiation: brachytherapy;   Radiation: radiation therapy
Sponsors:   Case Comprehensive Cancer Center;   National Cancer Institute (NCI)
Completed - verified February 2010

Conditions:   Breast Cancer;   Chronic Myeloproliferative Disorders;   Gestational Trophoblastic Tumor;   Graft Versus Host Disease;   Leukemia;   Lymphoma;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Diseases;   Neuroblastoma;   Ovarian Cancer;   Testicular Germ Cell Tumor
Interventions:   Biological: alemtuzumab;   Drug: methylprednisolone;   Drug: tacrolimus
Sponsors:   Case Comprehensive Cancer Center;   National Cancer Institute (NCI)
Completed - verified February 2010

Conditions:   Lymphoma;   Non-melanomatous Skin Cancer;   Precancerous Condition
Intervention:   Drug: silicon phthalocyanine 4
Sponsors:   Case Comprehensive Cancer Center;   National Cancer Institute (NCI)
Active, not recruiting - verified March 2010

Conditions:   Leukemia;   Myelodysplastic Syndromes
Intervention:   Drug: ispinesib
Sponsors:   Case Comprehensive Cancer Center;   National Cancer Institute (NCI)
Active, not recruiting - verified March 2010

Conditions:   Fallopian Tube Cancer;   Ovarian Cancer;   Peritoneal Cavity Cancer
Interventions:   Drug: carboplatin;   Drug: paclitaxel;   Drug: sorafenib tosylate
Sponsors:   Case Comprehensive Cancer Center;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Unspecified Adult Solid Tumor, Protocol Specific
Interventions:   Drug: becatecarin;   Drug: oxaliplatin
Sponsors:   Case Comprehensive Cancer Center;   National Cancer Institute (NCI)
Completed - verified February 2010

Conditions:   Esophageal Cancer;   Gastric Cancer
Interventions:   Drug: capecitabine;   Drug: irinotecan hydrochloride;   Drug: oxaliplatin
Sponsors:   Case Comprehensive Cancer Center;   National Cancer Institute (NCI)
Completed - verified March 2010

Condition:   Head and Neck Cancer
Interventions:   Biological: filgrastim;   Biological: pegfilgrastim;   Drug: cisplatin;   Drug: doxorubicin hydrochloride;   Drug: fosbretabulin disodium;   Radiation: radiation therapy
Sponsors:   Case Comprehensive Cancer Center;   National Cancer Institute (NCI)
Completed - verified March 2010

Condition:   Breast Cancer
Interventions:   Drug: celecoxib;   Drug: vinorelbine ditartrate
Sponsors:   Case Comprehensive Cancer Center;   National Cancer Institute (NCI)
Completed - verified February 2010

Conditions:   Leukemia;   Lymphoma
Interventions:   Biological: rituximab;   Drug: bortezomib;   Drug: fludarabine phosphate
Sponsors:   Case Comprehensive Cancer Center;   National Cancer Institute (NCI)
Active, not recruiting - verified March 2010

Conditions:   Chronic Myeloproliferative Disorders;   Leukemia;   Lymphoma;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Diseases
Interventions:   Biological: anti-thymocyte globulin;   Drug: cyclophosphamide;   Drug: cyclosporine;   Drug: fludarabine phosphate;   Drug: methylprednisolone;   Procedure: UV light therapy;   Procedure: allogeneic bone marrow transplantation;   Procedure: peripheral blood stem cell transplantation
Sponsors:   Case Comprehensive Cancer Center;   National Cancer Institute (NCI)
Completed - verified February 2010

Condition:   Head and Neck Cancer
Intervention:   Drug: fosbretabulin disodium
Sponsors:   Case Comprehensive Cancer Center;   National Cancer Institute (NCI)
Completed - verified March 2010

Condition:   Lymphoma
Interventions:   Drug: bryostatin 1;   Drug: vincristine sulfate
Sponsors:   Case Comprehensive Cancer Center;   National Cancer Institute (NCI)
Active, not recruiting - verified March 2010

Condition:   Lymphoma
Interventions:   Biological: rituximab;   Drug: cyclophosphamide;   Drug: doxorubicin hydrochloride;   Drug: prednisone;   Drug: vincristine sulfate;   Genetic: microarray analysis
Sponsors:   Case Comprehensive Cancer Center;   National Cancer Institute (NCI)
Completed - verified February 2010

Conditions:   Leukemia;   Lymphoma;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Diseases
Interventions:   Drug: busulfan;   Drug: cyclophosphamide;   Drug: cytarabine;   Radiation: radiation therapy
Sponsors:   Case Comprehensive Cancer Center;   National Cancer Institute (NCI)
Active, not recruiting - verified March 2010

Conditions:   Chronic Myeloproliferative Disorders;   Leukemia;   Lymphoma;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Diseases
Interventions:   Biological: anti-thymocyte globulin;   Biological: filgrastim;   Drug: cyclophosphamide;   Drug: fludarabine phosphate;   Procedure: umbilical cord blood transplantation;   Drug: methylprednisolone
Sponsors:   Case Comprehensive Cancer Center;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Breast Cancer
Interventions:   Drug: docetaxel;   Drug: erlotinib hydrochloride
Sponsors:   Case Comprehensive Cancer Center;   National Cancer Institute (NCI)
Active, not recruiting - verified February 2010

Condition:   Breast Cancer
Interventions:   Procedure: adjuvant therapy;   Procedure: conventional surgery;   Radiation: intraoperative radiation therapy
Sponsors:   Case Comprehensive Cancer Center;   National Cancer Institute (NCI)
Completed - verified February 2010

Condition:   Lung Cancer
Interventions:   Drug: thalidomide;   Procedure: adjuvant therapy
Sponsors:   Case Comprehensive Cancer Center;   National Cancer Institute (NCI)
Active, not recruiting - verified February 2010

Conditions:   Leukemia;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Diseases
Interventions:   Drug: carboplatin;   Drug: fludarabine phosphate;   Drug: thalidomide;   Drug: topotecan hydrochloride
Sponsors:   Case Comprehensive Cancer Center;   National Cancer Institute (NCI)
Completed - verified February 2010

Condition:   Cancer
Interventions:   Drug: docetaxel;   Drug: thalidomide
Sponsors:   Case Comprehensive Cancer Center;   National Cancer Institute (NCI)
Completed - verified February 2010

Condition:   Head and Neck Cancer
Interventions:   Drug: docetaxel;   Drug: erlotinib hydrochloride;   Procedure: conventional surgery;   Radiation: radiation therapy
Sponsors:   Case Comprehensive Cancer Center;   National Cancer Institute (NCI)
Active, not recruiting - verified February 2010

Condition:   Lymphoma
Interventions:   Biological: filgrastim;   Drug: cyclophosphamide;   Drug: etoposide;   Drug: lomustine;   Drug: procarbazine hydrochloride
Sponsors:   Case Comprehensive Cancer Center;   National Cancer Institute (NCI)
Completed - verified February 2010

Conditions:   Leukemia;   Lymphoma
Interventions:   Biological: sargramostim;   Drug: cytarabine;   Drug: mitoxantrone hydrochloride
Sponsors:   Case Comprehensive Cancer Center;   National Cancer Institute (NCI)
Completed - verified February 2010

Condition:   Lymphoma
Interventions:   Biological: filgrastim;   Biological: rituximab;   Drug: carmustine;   Drug: cisplatin;   Drug: cyclophosphamide;   Drug: etoposide;   Procedure: bone marrow ablation with stem cell support;   Procedure: peripheral blood stem cell transplantation;   Radiation: radiation therapy
Sponsors:   Case Comprehensive Cancer Center;   National Cancer Institute (NCI)
Completed - verified March 2010

Condition:   Breast Cancer
Interventions:   Biological: bevacizumab;   Drug: cyclophosphamide;   Drug: docetaxel;   Drug: doxorubicin hydrochloride;   Procedure: adjuvant therapy;   Procedure: conventional surgery;   Procedure: neoadjuvant therapy;   Radiation: radiation therapy
Sponsors:   Case Comprehensive Cancer Center;   National Cancer Institute (NCI)
Active, not recruiting - verified February 2010

Conditions:   Brain and Central Nervous System Tumors;   Chronic Myeloproliferative Disorders;   Gastrointestinal Stromal Tumor;   Leukemia;   Lymphoma;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Diseases;   Precancerous/Nonmalignant Condition;   Small Intestine Cancer;   Unspecified Adult Solid Tumor, Protocol Specific
Intervention:   Drug: imatinib mesylate
Sponsors:   Case Comprehensive Cancer Center;   National Cancer Institute (NCI)
Completed - verified February 2010

Conditions:   Chronic Myeloproliferative Disorders;   Gastrointestinal Stromal Tumor;   Leukemia;   Lymphoma;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Diseases;   Precancerous Condition;   Small Intestine Cancer;   Unspecified Adult Solid Tumor, Protocol Specific
Intervention:   Drug: imatinib mesylate
Sponsors:   University of Pittsburgh;   National Cancer Institute (NCI)
Completed - verified April 2004

Conditions:   Breast Cancer;   Head and Neck Cancer;   Lymphoma;   Metastatic Cancer;   Non-melanomatous Skin Cancer;   Sarcoma
Intervention:   Drug: silicon phthalocyanine 4
Sponsors:   Case Comprehensive Cancer Center;   National Cancer Institute (NCI)
Completed - verified March 2010

Condition:   Sarcoma
Interventions:   Biological: dactinomycin;   Drug: busulfan;   Drug: doxorubicin hydrochloride;   Drug: etoposide;   Drug: ifosfamide;   Drug: melphalan;   Drug: vincristine sulfate;   Procedure: autologous hematopoietic stem cell transplantation;   Procedure: conventional surgery;   Radiation: radiation therapy
Sponsors:   University Hospitals, Leicester;   National Cancer Institute (NCI);   Children's Cancer and Leukaemia Group;   Societe Francaise Oncologie Pediatrique;   European Organization for Research and Treatment of Cancer;   Gesellschaft fur Padiatrische Onkologie und Hamatologie - Germany;   Gesellschaft fur Padiatrische Onkologie und Hamatologie - Austria;   Swiss Group for Clinical Cancer Research;   EBMT Solid Tumors Working Party;   Children's Oncology Group
Recruiting - verified March 2010

Condition:   Leukemia
Interventions:   Drug: asparaginase;   Drug: busulfan;   Drug: cyclophosphamide;   Drug: cyclosporine;   Drug: cytarabine;   Drug: daunorubicin hydrochloride;   Drug: dexamethasone;   Drug: etoposide;   Drug: leucovorin calcium;   Drug: mercaptopurine;   Drug: methotrexate;   Drug: prednisolone;   Drug: prednisone;   Drug: thioguanine;   Drug: vincristine sulfate;   Procedure: allogeneic bone marrow transplantation
Sponsor:   Dutch Childhood Oncology Group
Active, not recruiting - verified October 2006

Condition:   Breast Cancer
Interventions:   Biological: filgrastim;   Drug: cyclophosphamide;   Drug: doxorubicin hydrochloride;   Drug: paclitaxel;   Drug: tamoxifen citrate;   Procedure: adjuvant therapy;   Radiation: radiation therapy
Sponsors:   Case Comprehensive Cancer Center;   National Cancer Institute (NCI)
Active, not recruiting - verified February 2010

Condition:   Unspecified Adult Solid Tumor, Protocol Specific
Interventions:   Drug: capecitabine;   Drug: irinotecan hydrochloride;   Drug: oxaliplatin
Sponsors:   Case Comprehensive Cancer Center;   National Cancer Institute (NCI)
Completed - verified February 2010

Condition:   Unspecified Adult Solid Tumor, Protocol Specific
Interventions:   Drug: gemcitabine hydrochloride;   Drug: pegylated liposomal doxorubicin hydrochloride;   Drug: vinorelbine ditartrate
Sponsors:   Case Comprehensive Cancer Center;   National Cancer Institute (NCI)
Completed - verified March 2010

Conditions:   Chronic Myeloproliferative Disorders;   Leukemia;   Lymphoma;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Diseases;   Precancerous/Nonmalignant Condition;   Small Intestine Cancer
Interventions:   Biological: anti-thymocyte globulin;   Biological: graft-versus-tumor induction therapy;   Drug: cyclophosphamide;   Drug: fludarabine phosphate;   Procedure: peripheral blood stem cell transplantation
Sponsors:   Case Comprehensive Cancer Center;   National Cancer Institute (NCI)
Active, not recruiting - verified February 2010

Condition:   Metastatic Cancer
Intervention:   Radiation: stereotactic radiosurgery
Sponsors:   Case Comprehensive Cancer Center;   National Cancer Institute (NCI)
Active, not recruiting - verified March 2010

Condition:   Breast Cancer
Interventions:   Drug: paclitaxel;   Procedure: adjuvant therapy;   Radiation: radiation therapy
Sponsors:   Case Comprehensive Cancer Center;   National Cancer Institute (NCI)
Active, not recruiting - verified February 2010

Condition:   Breast Cancer
Interventions:   Drug: cisplatin;   Drug: etoposide;   Drug: ifosfamide;   Drug: Mesna
Sponsors:   Case Comprehensive Cancer Center;   National Cancer Institute (NCI)
Completed - verified February 2010

Condition:   Breast Cancer
Interventions:   Biological: therapeutic allogeneic lymphocytes;   Drug: cyclophosphamide;   Drug: docetaxel;   Drug: doxorubicin hydrochloride;   Drug: fludarabine phosphate;   Procedure: peripheral blood stem cell transplantation
Sponsors:   Case Comprehensive Cancer Center;   National Cancer Institute (NCI)
Active, not recruiting - verified February 2010

Conditions:   Kidney Cancer;   Metastatic Cancer;   Unspecified Adult Solid Tumor, Protocol Specific
Interventions:   Procedure: radiofrequency ablation;   Procedure: thermal ablation therapy
Sponsors:   Case Comprehensive Cancer Center;   National Cancer Institute (NCI)
Completed - verified March 2010

Condition:   Unspecified Adult Solid Tumor, Protocol Specific
Interventions:   Drug: BMS-214662;   Drug: paclitaxel
Sponsors:   Case Comprehensive Cancer Center;   National Cancer Institute (NCI)
Active, not recruiting - verified February 2010

Conditions:   Extrahepatic Bile Duct Cancer;   Gallbladder Cancer;   Liver Cancer
Intervention:   Drug: becatecarin
Sponsors:   Case Comprehensive Cancer Center;   National Cancer Institute (NCI)
Completed - verified February 2010

Condition:   Colorectal Cancer
Interventions:   Drug: O6-benzylguanine;   Drug: carmustine
Sponsors:   Case Comprehensive Cancer Center;   National Cancer Institute (NCI)
Completed - verified February 2010

Condition:   Lung Cancer
Intervention:   Drug: becatecarin
Sponsors:   Case Comprehensive Cancer Center;   National Cancer Institute (NCI)
Completed - verified February 2010

Condition:   Breast Cancer
Interventions:   Drug: doxorubicin hydrochloride;   Drug: semaxanib;   Procedure: conventional surgery;   Radiation: radiation therapy;   Drug: tamoxifen
Sponsors:   Case Comprehensive Cancer Center;   National Cancer Institute (NCI)
Completed - verified February 2010

Condition:   Unspecified Adult Solid Tumor, Protocol Specific
Interventions:   Drug: cisplatin;   Drug: fenretinide;   Drug: paclitaxel
Sponsors:   Case Comprehensive Cancer Center;   National Cancer Institute (NCI)
Completed - verified February 2010

Conditions:   Leukemia;   Myelodysplastic Syndromes
Interventions:   Drug: carboplatin;   Drug: fludarabine phosphate;   Drug: topotecan hydrochloride
Sponsors:   Case Comprehensive Cancer Center;   National Cancer Institute (NCI)
Completed - verified March 2010

Condition:   Head and Neck Cancer
Interventions:   Drug: paclitaxel;   Drug: semaxanib
Sponsors:   Case Comprehensive Cancer Center;   National Cancer Institute (NCI)
Completed - verified February 2010

Condition:   Unspecified Adult Solid Tumor, Protocol Specific
Intervention:   Drug: semaxanib
Sponsors:   Case Comprehensive Cancer Center;   National Cancer Institute (NCI)
Completed - verified February 2010

Condition:   Multiple Myeloma and Plasma Cell Neoplasm
Interventions:   Drug: O6-benzylguanine;   Drug: carmustine
Sponsors:   Case Comprehensive Cancer Center;   National Cancer Institute (NCI)
Completed - verified February 2010

Conditions:   Fallopian Tube Cancer;   Ovarian Cancer;   Peritoneal Cavity Cancer
Intervention:   Drug: chemotherapy
Sponsors:   Medical Research Council;   European Organization for Research and Treatment of Cancer
Active, not recruiting - verified September 2005

Condition:   Head and Neck Cancer
Interventions:   Biological: bleomycin sulfate;   Drug: fluorouracil;   Drug: leucovorin calcium;   Drug: methotrexate;   Drug: vincristine sulfate;   Radiation: low-LET cobalt-60 gamma ray therapy;   Radiation: low-LET photon therapy;   Radiation: radiation therapy
Sponsor:   Cancer Research UK
Active, not recruiting - verified March 2010

Conditions:   Leukemia;   Lymphoma;   Multiple Myeloma and Plasma Cell Neoplasm
Interventions:   Drug: bryostatin 1;   Drug: vincristine sulfate
Sponsors:   Case Comprehensive Cancer Center;   National Cancer Institute (NCI)
Active, not recruiting - verified February 2010

Condition:   Breast Cancer
Interventions:   Biological: filgrastim;   Drug: CMF regimen;   Drug: docetaxel;   Drug: doxorubicin hydrochloride;   Drug: tamoxifen citrate;   Procedure: autologous bone marrow transplantation;   Procedure: surgical procedure;   Radiation: radiation therapy
Sponsors:   Case Comprehensive Cancer Center;   National Cancer Institute (NCI)
Active, not recruiting - verified February 2010

Conditions:   Leukemia;   Lymphoma;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Diseases
Interventions:   Biological: filgrastim;   Drug: busulfan;   Drug: cyclophosphamide;   Drug: cyclosporine;   Procedure: bone marrow ablation with stem cell support;   Procedure: peripheral blood stem cell transplantation
Sponsors:   Case Comprehensive Cancer Center;   National Cancer Institute (NCI)
Completed - verified March 2010

Condition:   Lymphoma
Interventions:   Biological: filgrastim;   Drug: cyclophosphamide;   Drug: etoposide;   Drug: lomustine;   Drug: procarbazine hydrochloride;   Radiation: radiation therapy
Sponsors:   Case Comprehensive Cancer Center;   National Cancer Institute (NCI)
Completed - verified February 2010

Condition:   Lymphoma
Interventions:   Drug: O6-benzylguanine;   Drug: carmustine
Sponsors:   Case Comprehensive Cancer Center;   National Cancer Institute (NCI)
Completed - verified February 2010

Condition:   Lymphoma
Interventions:   Biological: filgrastim;   Drug: cyclophosphamide;   Drug: etoposide;   Drug: lomustine;   Drug: procarbazine hydrochloride;   Radiation: radiation therapy
Sponsors:   Case Comprehensive Cancer Center;   National Cancer Institute (NCI)
Active, not recruiting - verified February 2010

Condition:   Lymphoma
Intervention:   Biological: bleomycin sulfate
Sponsors:   Case Comprehensive Cancer Center;   National Cancer Institute (NCI)
Active, not recruiting - verified February 2010

Conditions:   Graft Versus Host Disease;   Leukemia;   Lymphoma;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Diseases
Interventions:   Biological: anti-thymocyte globulin;   Drug: busulfan;   Drug: cyclosporine;   Drug: melphalan;   Drug: methylprednisolone;   Procedure: umbilical cord blood transplantation;   Radiation: radiation therapy
Sponsors:   Case Comprehensive Cancer Center;   National Cancer Institute (NCI)
Active, not recruiting - verified March 2010

Condition:   Unspecified Adult Solid Tumor, Protocol Specific
Interventions:   Drug: O6-benzylguanine;   Drug: carmustine;   Drug: chemosensitization/potentiation therapy
Sponsors:   Case Comprehensive Cancer Center;   National Cancer Institute (NCI)
Completed - verified February 2010

Conditions:   Leukemia;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Diseases
Interventions:   Biological: anti-thymocyte globulin;   Drug: busulfan;   Drug: cyclophosphamide;   Drug: melphalan;   Drug: methylprednisolone;   Procedure: bone marrow ablation with stem cell support;   Procedure: umbilical cord blood transplantation;   Radiation: radiation therapy
Sponsors:   Case Comprehensive Cancer Center;   National Cancer Institute (NCI)
Completed - verified February 2010

Condition:   Kidney Cancer
Interventions:   Drug: cisplatin;   Drug: gemcitabine hydrochloride
Sponsors:   Case Comprehensive Cancer Center;   National Cancer Institute (NCI)
Completed - verified February 2010

Condition:   Lung Cancer
Intervention:   Drug: aminocamptothecin colloidal dispersion
Sponsors:   Case Comprehensive Cancer Center;   National Cancer Institute (NCI)
Active, not recruiting - verified February 2010

Conditions:   Brain and Central Nervous System Tumors;   Lymphoma;   Unspecified Adult Solid Tumor, Protocol Specific
Interventions:   Biological: filgrastim;   Biological: sargramostim;   Biological: therapeutic autologous lymphocytes;   Drug: O6-benzylguanine;   Drug: carmustine;   Drug: temozolomide;   Procedure: in vitro-treated peripheral blood stem cell transplantation
Sponsors:   Case Comprehensive Cancer Center;   National Cancer Institute (NCI)
Completed - verified February 2010

Condition:   Colorectal Cancer
Intervention:   Drug: irinotecan hydrochloride
Sponsors:   Case Comprehensive Cancer Center;   National Cancer Institute (NCI)
Active, not recruiting - verified February 2010

Condition:   Lymphoma
Interventions:   Biological: filgrastim;   Drug: lomustine;   Drug: procarbazine hydrochloride;   Radiation: radiation therapy
Sponsors:   Case Comprehensive Cancer Center;   National Cancer Institute (NCI)
Active, not recruiting - verified March 2010

Condition:   Leukemia
Interventions:   Drug: etoposide;   Drug: topotecan hydrochloride
Sponsors:   Case Comprehensive Cancer Center;   National Cancer Institute (NCI)
Completed - verified February 2010